Jennifer L Goldman1,2, Troy Richardson3, Jason G Newland1,2, Brian Lee1,2, Jeffrey S Gerber4, Matt Hall3, Matthew Kronman5, Adam L Hersh6. 1. Children's Mercy Hospitals and Clinics, Kansas City, Missouri. 2. University of Missouri-Kansas City. 3. Children's Hospital Association, Overland Park, Kansas. 4. Children's Hospital of Philadelphia, Pennsylvania. 5. Seattle Children's, Washington. 6. University of Utah School of Medicine, Salt Lake City.
Abstract
BACKGROUND: Outpatient parenteral antimicrobial therapy (OPAT) is overused in cases where highly bioavailable oral alternatives would be equally effective. However, the scope of OPAT use for children nationwide is poorly understood. Our objective was to characterize OPAT use and clinical outcomes for a large population of pediatric Medicaid enrollees treated with OPAT. METHODS: We analyzed the Truven MarketScan Medicaid claims database between 2009 and 2012. An OPAT episode was identified by capturing children with claims data indicating home infusion therapy for an intravenous antimicrobial. We characterized OPAT use by describing patient demographics, diagnoses, and antimicrobials prescribed. We categorized an antimicrobial as highly bioavailable if ≥80% systemic exposure was expected from the peroral dose. We also determined the percentage of OPAT recipients in whom a follow-up healthcare encounter occurred during the OPAT episode in either the emergency department or as a hospital admission. We reviewed the primary diagnoses associated with these healthcare encounters to determine whether it was related to OPAT. RESULTS: We identified 3433 OPAT episodes in 2687 patients. A total of 4774 antimicrobials were prescribed during these episodes. Ceftriaxone and vancomycin were the most commonly prescribed antimicrobials. Highly bioavailable antimicrobials accounted for 34% of antimicrobials used for OPAT. An emergency department visit or hospital admission occurred during 38% of OPAT episodes, among which 61% were OPAT-related. CONCLUSIONS: The high rate of medical encounters associated with OPAT in this cohort and the common prescribing of highly bioavailable antimicrobials underscore the opportunities for antimicrobial stewardship of pediatric OPAT.
BACKGROUND: Outpatient parenteral antimicrobial therapy (OPAT) is overused in cases where highly bioavailable oral alternatives would be equally effective. However, the scope of OPAT use for children nationwide is poorly understood. Our objective was to characterize OPAT use and clinical outcomes for a large population of pediatric Medicaid enrollees treated with OPAT. METHODS: We analyzed the Truven MarketScan Medicaid claims database between 2009 and 2012. An OPAT episode was identified by capturing children with claims data indicating home infusion therapy for an intravenous antimicrobial. We characterized OPAT use by describing patient demographics, diagnoses, and antimicrobials prescribed. We categorized an antimicrobial as highly bioavailable if ≥80% systemic exposure was expected from the peroral dose. We also determined the percentage of OPAT recipients in whom a follow-up healthcare encounter occurred during the OPAT episode in either the emergency department or as a hospital admission. We reviewed the primary diagnoses associated with these healthcare encounters to determine whether it was related to OPAT. RESULTS: We identified 3433 OPAT episodes in 2687 patients. A total of 4774 antimicrobials were prescribed during these episodes. Ceftriaxone and vancomycin were the most commonly prescribed antimicrobials. Highly bioavailable antimicrobials accounted for 34% of antimicrobials used for OPAT. An emergency department visit or hospital admission occurred during 38% of OPAT episodes, among which 61% were OPAT-related. CONCLUSIONS: The high rate of medical encounters associated with OPAT in this cohort and the common prescribing of highly bioavailable antimicrobials underscore the opportunities for antimicrobial stewardship of pediatric OPAT.
Authors: Emily Sydnor Spivak; Brian Kendall; Patricia Orlando; Christian Perez; Marina De Amorim; Matthew Samore; Andrew T Pavia; Adam L Hersh Journal: Infect Control Hosp Epidemiol Date: 2015-05-26 Impact factor: 3.254
Authors: Jason D Fraser; Pablo Aguayo; Charles M Leys; Scott J Keckler; Jason G Newland; Susan W Sharp; John P Murphy; Charles L Snyder; Ronald J Sharp; Walter S Andrews; George W Holcomb; Daniel J Ostlie; Shawn D St Peter Journal: J Pediatr Surg Date: 2010-06 Impact factor: 2.545
Authors: Aarthi Chary; Alan D Tice; Lawrence P Martinelli; Laura A Liedtke; Melissa S Plantenga; Larry J Strausbaugh Journal: Clin Infect Dis Date: 2006-10-10 Impact factor: 9.079
Authors: A Freifeld; D Marchigiani; T Walsh; S Chanock; L Lewis; J Hiemenz; S Hiemenz; J E Hicks; V Gill; S M Steinberg; P A Pizzo Journal: N Engl J Med Date: 1999-07-29 Impact factor: 91.245
Authors: Joseph L Kuti; Thuy N Le; Charles H Nightingale; David P Nicolau; Richard Quintiliani Journal: Am J Health Syst Pharm Date: 2002-11-15 Impact factor: 2.637
Authors: Makoto Jones; Benedikt Huttner; Karl Madaras-Kelly; Kevin Nechodom; Christopher Nielson; Matthew Bidwell Goetz; Melinda M Neuhauser; Matthew H Samore; Michael A Rubin Journal: Infect Control Hosp Epidemiol Date: 2012-04 Impact factor: 3.254
Authors: Emily J Godbout; Amy L Pakyz; John Daniel Markley; Andrew J Noda; Michael P Stevens Journal: Curr Infect Dis Rep Date: 2018-08-01 Impact factor: 3.725
Authors: Nathan M Krah; Tyler Bardsley; Richard Nelson; Lawanda Esquibel; Mark Crosby; Carrie L Byington; Andrew T Pavia; Adam L Hersh Journal: Hosp Pediatr Date: 2019-04
Authors: Katie J Suda; Lauri A Hicks; Rebecca M Roberts; Robert J Hunkler; Linda M Matusiak; Glen T Schumock Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 20.999
Authors: Bernie Carter; Enitan D Carrol; David Porter; Matthew Peak; David Taylor-Robinson; Debra Fisher-Smith; Lucy Blake Journal: BMJ Open Date: 2018-11-15 Impact factor: 2.692